BRPI0818193B8 - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0818193B8
BRPI0818193B8 BRPI0818193A BRPI0818193A BRPI0818193B8 BR PI0818193 B8 BRPI0818193 B8 BR PI0818193B8 BR PI0818193 A BRPI0818193 A BR PI0818193A BR PI0818193 A BRPI0818193 A BR PI0818193A BR PI0818193 B8 BRPI0818193 B8 BR PI0818193B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
hydrogen atom
bicyclic
gamma
Prior art date
Application number
BRPI0818193A
Other languages
English (en)
Inventor
Kawamura Asuka
Shimada Kousei
Arakawa Naohisa
Domon Yuki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to BR122013020635-3A priority Critical patent/BR122013020635A2/pt
Publication of BRPI0818193A2 publication Critical patent/BRPI0818193A2/pt
Publication of BRPI0818193B1 publication Critical patent/BRPI0818193B1/pt
Publication of BRPI0818193B8 publication Critical patent/BRPI0818193B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
    • C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/623—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
    • C07C49/627—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings the condensed ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto. pretende-se proporcionar um derivado de (gama)-amino ácido bicíclico tendo excelente atividade como um ligante de (alfa2delta). a presente invenção proporciona um composto representado pela fórmula geral (i): (i) em que r1, r2, r2', r4, r5, r6, r7, r8 e r8' são um átomo de hidrogênio ou semelhante; e r3 é um átomo de hidrogênio, um átomo de halogênio, um grupo c1-c6 alquila ou semelhante.
BRPI0818193A 2007-09-28 2008-09-25 composto, composição farmacêutica, e, uso de um composto BRPI0818193B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122013020635-3A BR122013020635A2 (pt) 2007-09-28 2008-09-25 Composto

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-255430 2007-09-28
JP2007255430 2007-09-28
PCT/JP2008/067223 WO2009041453A1 (ja) 2007-09-28 2008-09-25 二環性γ－アミノ酸誘導体

Publications (3)

Publication Number Publication Date
BRPI0818193A2 BRPI0818193A2 (pt) 2017-12-12
BRPI0818193B1 BRPI0818193B1 (pt) 2020-11-10
BRPI0818193B8 true BRPI0818193B8 (pt) 2021-05-25

Family

ID=40511336

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0818193A BRPI0818193B8 (pt) 2007-09-28 2008-09-25 composto, composição farmacêutica, e, uso de um composto
BR122013020635-3A BR122013020635A2 (pt) 2007-09-28 2008-09-25 Composto

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122013020635-3A BR122013020635A2 (pt) 2007-09-28 2008-09-25 Composto

Country Status (25)

Country Link
US (1) US7947738B2 (pt)
EP (2) EP2192109B1 (pt)
JP (1) JP4479974B2 (pt)
KR (2) KR101409079B1 (pt)
CN (2) CN103483169A (pt)
AU (1) AU2008304933B2 (pt)
BR (2) BRPI0818193B8 (pt)
CA (1) CA2701110C (pt)
CO (1) CO6270314A2 (pt)
CY (1) CY1114836T1 (pt)
DK (1) DK2192109T3 (pt)
ES (2) ES2531324T3 (pt)
HR (1) HRP20130935T1 (pt)
IL (1) IL204621A (pt)
MX (1) MX2010003394A (pt)
MY (2) MY172034A (pt)
NZ (1) NZ584699A (pt)
PH (1) PH12013501663B1 (pt)
PL (1) PL2192109T3 (pt)
PT (1) PT2192109E (pt)
RU (1) RU2446148C2 (pt)
SI (1) SI2192109T1 (pt)
TW (2) TWI526425B (pt)
WO (1) WO2009041453A1 (pt)
ZA (1) ZA201002013B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101409079B1 (ko) 2007-09-28 2014-06-18 다이이찌 산쿄 가부시키가이샤 2 고리성 γ-아미노산 유도체
WO2010079668A1 (ja) * 2009-01-08 2010-07-15 第一三共株式会社 オレフィン化合物
KR101674700B1 (ko) * 2009-03-26 2016-11-09 다이이찌 산쿄 가부시키가이샤 2고리성 γ-아미노산 유도체의 제조 방법
WO2012169475A1 (ja) * 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
EP2719676B1 (en) * 2011-06-08 2017-12-13 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via iminium salt
ES2686929T3 (es) 2011-12-15 2018-10-22 Daiichi Sankyo Company, Limited Procedimiento de resolución óptica para compuesto bicíclico utilizando catalizador asimétrico
WO2013089189A1 (ja) * 2011-12-16 2013-06-20 第一三共株式会社 ヒドロキシスルホン酸を経由する二環性化合物の光学分割方法
KR101951379B1 (ko) * 2012-02-08 2019-02-22 스텔라파머 가부시키가이샤 세레울라이드 및 그 유도체의 제조 방법, 세레울라이드 제조를 위한 중간체 및 세레울라이드 유도체
KR101976891B1 (ko) 2012-04-10 2019-05-09 다이이찌 산쿄 가부시키가이샤 효소를 사용하는 2 고리성 화합물의 광학 분할 방법
TWI645863B (zh) * 2013-04-04 2019-01-01 日商第一三共股份有限公司 胺基羧酸之鹽的固形組成物
TWI635071B (zh) * 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
US9663479B2 (en) 2013-12-18 2017-05-30 Novassay S.A. γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders
BR112017019918B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para produzir uma preparação sólida farmacêutica para estabilizar uma preparação sólida farmacêutica
US10603285B2 (en) 2015-03-19 2020-03-31 Daiichi Sankyo Company, Limited Solid preparation including colorant
CN107848953B (zh) * 2015-12-25 2021-05-18 四川海思科制药有限公司 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用
CN107848952B (zh) * 2015-12-31 2021-04-09 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
CN106928080B (zh) * 2015-12-31 2020-12-25 四川海思科制药有限公司 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用
WO2017183539A1 (ja) * 2016-04-18 2017-10-26 第一三共株式会社 メルドラム酸を用いる二環性化合物の製造方法
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法
ES2906887T3 (es) * 2016-07-21 2022-04-20 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivado del indol usado como inhibidor de CRTH2
KR102335089B1 (ko) * 2016-09-14 2021-12-02 스촨 하이스코 파마수티컬 씨오., 엘티디 융합 트리사이클릭 γ-아미노산 유도체, 그 제조방법, 및 그것의 의료 용도
JP7051332B2 (ja) * 2017-08-23 2022-04-11 キヤノン株式会社 有機化合物及び光電変換素子
JP7222063B2 (ja) * 2018-07-12 2023-02-14 四川海思科制▲薬▼有限公司 縮合三環性γ－アミノ酸誘導体の組成物及びその調製
WO2020011258A1 (zh) * 2018-07-12 2020-01-16 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用
WO2020027019A1 (ja) * 2018-07-30 2020-02-06 第一三共株式会社 安定化剤を含有する医薬品の固形製剤
CN112384493B (zh) * 2018-08-09 2023-06-06 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物的制备方法及中间体
CN114402198A (zh) * 2019-09-03 2022-04-26 四川海思科制药有限公司 2-((1s,2s,3r,6s,8s)-2-(氨甲基)三环[4.2.1.03,8]壬烷-2-基)乙酸苯磺酸盐或其组合物杂质检测方法
CN110511141B (zh) * 2019-09-09 2022-04-29 上海凌凯医药科技有限公司 一种丙戊酰脲的合成方法
AU2020370758B2 (en) * 2019-10-25 2025-08-14 Kyoto University Preventative or therapeutic agent for tauopathy
CN110818582B (zh) * 2019-11-20 2023-06-09 合肥拓锐生物科技有限公司 一种gaba类似物及其盐，及其合成方法、应用、药物
CN111116345A (zh) * 2019-12-30 2020-05-08 上海华理生物医药股份有限公司 一种制备Mirogabalin的新方法
JP7728884B2 (ja) 2021-05-12 2025-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ｃＧＡＳ阻害剤としてのＣ結合環状置換基を有するピリジン誘導体
CN114195661B (zh) * 2021-12-21 2023-12-22 苏州楚凯药业有限公司 一种苯磺酸米洛巴林的制备方法
CN117986143A (zh) * 2022-11-03 2024-05-07 中科中山药物创新研究院 含有多环结构的γ-氨基丁酸衍生物及其制备方法和用途
CN121218983A (zh) 2023-06-02 2025-12-26 第一三共株式会社 含有米洛巴林的医药组合物
CN116903468B (zh) * 2023-07-14 2024-01-26 山东新时代药业有限公司 一种米洛巴林中间体的制备方法
CN117623957A (zh) * 2023-12-04 2024-03-01 中国药科大学 一种米洛巴林苯磺酸盐非对映异构体[（1r,5s,6r）-6-（氨基甲基）-3-乙基双环[3.2.0]庚-3-烯-6-基]乙酸苯磺酸盐的合成方法
CN117800858B (zh) * 2023-12-28 2024-06-21 南京津泓科技有限公司 一种米洛巴林催化氰基化制备方法
TW202535348A (zh) * 2024-01-08 2025-09-16 大陸商海思科醫藥集團股份有限公司 一種稠合三環γ－氨基酸衍生物在治療中樞神經病理性疼痛中的用途
CN118420477B (zh) * 2024-07-01 2024-10-29 中节能万润股份有限公司 一种苯磺酸米洛巴林的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547766A1 (de) * 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
KR100589066B1 (ko) 1997-10-27 2006-06-13 워너-램버트 캄파니 엘엘씨 약제로서 유용한 시클릭 아미노산 및 그의 유도체
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
WO2002085839A1 (en) * 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
AU2003248907B2 (en) 2002-07-11 2007-04-26 Merck & Co., Inc. Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds
GB0223072D0 (en) * 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR101409079B1 (ko) 2007-09-28 2014-06-18 다이이찌 산쿄 가부시키가이샤 2 고리성 γ-아미노산 유도체

Also Published As

Publication number Publication date
HK1139381A1 (en) 2010-09-17
EP2657219A1 (en) 2013-10-30
IL204621A0 (en) 2010-11-30
CO6270314A2 (es) 2011-04-20
IL204621A (en) 2013-04-30
HRP20130935T1 (hr) 2013-11-22
NZ584699A (en) 2011-04-29
CN101878193B (zh) 2014-07-09
MY172034A (en) 2019-11-12
JPWO2009041453A1 (ja) 2011-01-27
US20100249229A1 (en) 2010-09-30
KR20100065342A (ko) 2010-06-16
PH12013501663B1 (en) 2018-09-07
EP2192109A1 (en) 2010-06-02
SI2192109T1 (sl) 2014-03-31
BRPI0818193B1 (pt) 2020-11-10
ES2531324T3 (es) 2015-03-13
PH12013501663A1 (en) 2015-02-09
CA2701110A1 (en) 2009-04-02
TW200924743A (en) 2009-06-16
AU2008304933B2 (en) 2011-02-24
CN101878193A (zh) 2010-11-03
ZA201002013B (en) 2010-11-24
KR20130093181A (ko) 2013-08-21
CA2701110C (en) 2013-01-08
PT2192109E (pt) 2013-12-09
RU2010116708A (ru) 2011-11-10
BR122013020635A2 (pt) 2019-08-06
ES2433890T3 (es) 2013-12-12
KR101409079B1 (ko) 2014-06-18
MY153910A (en) 2015-04-15
BRPI0818193A2 (pt) 2017-12-12
TW201439053A (zh) 2014-10-16
RU2446148C2 (ru) 2012-03-27
CN103483169A (zh) 2014-01-01
AU2008304933A1 (en) 2009-04-02
PL2192109T3 (pl) 2014-01-31
EP2192109B1 (en) 2013-09-04
US7947738B2 (en) 2011-05-24
WO2009041453A1 (ja) 2009-04-02
DK2192109T3 (da) 2013-12-16
JP4479974B2 (ja) 2010-06-09
EP2657219B1 (en) 2014-12-10
CY1114836T1 (el) 2016-12-14
HK1190698A1 (en) 2014-07-11
MX2010003394A (es) 2010-04-09
TWI436762B (zh) 2014-05-11
EP2192109A4 (en) 2012-04-18
KR101335784B1 (ko) 2013-12-05
TWI526425B (zh) 2016-03-21

Similar Documents

Publication Publication Date Title
MY153910A (en) BICYCLIC y-AMINO ACID DERIVATIVE
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
PH12017501192A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
BR112012033770A2 (pt) novo derivado de nicotinamida ou sal do mesmo
PH12016502037B1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
BR112014001018A2 (pt) derivado de azabenzimidazol tendo atividade de ativação de ampk
PA8852101A1 (es) Nucleótidos uracil ciclopropílicos
BRPI0517343A (pt) derivados de betulina, preparação destes e uso dos mesmos
BRPI1011683B8 (pt) derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
BR112012013511A2 (pt) derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear
TW200745058A (en) MMP-13 selective inhibitors
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
BR112015015275A8 (pt) composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF